APO866 lacks efficacy in cutaneous T-cell lymphoma

The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology.
Source: MedWire News - Category: Consumer Health News Tags: Lymphoma Source Type: news